Malolactone strikes: K-Ras-G12D's Achilles' heel

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• The Kirsten rat sarcoma viral oncogene homolog (K-Ras) protein plays a crucial role in cell signaling.
• Mutations in K-Ras, particularly the G12D variant, are frequently found in pancreatic cancers, driving tumor growth.
• Targeting K-Ras mutations presents a significant challenge in cancer therapy.

Purpose of the Study:

• To design and synthesize a first-in-class covalent inhibitor targeting the K-Ras-G12D mutation.
• To evaluate the efficacy of this novel inhibitor in preclinical models of pancreatic cancer.

Main Methods:

• Utilized malolactone-based electrophiles to exploit strain release for inhibitor design.
• Developed a covalent inhibitor specifically targeting the K-Ras-G12D variant.
• Assessed the compound's impact on oncogenic signaling pathways and tumor growth in relevant cancer models.

Main Results:

• Successfully designed and synthesized a novel covalent inhibitor targeting K-Ras-G12D.
• The inhibitor demonstrated significant inhibition of oncogenic signaling.
• Drastic reduction in tumor growth was observed in preclinical K-Ras-G12D-mutant pancreatic cancer models.

Conclusions:

• This study presents a promising first-in-class covalent inhibitor for K-Ras-G12D-mutant pancreatic cancer.
• The findings expand therapeutic strategies beyond existing K-Ras-G12C inhibitors.
• This represents a significant advancement in targeting a prevalent oncogenic driver in pancreatic cancer.